3rd World Congress on
Cancer Immunology and Immunotherapy

Gregory Lee received his Ph. D from the California Institute of Technology and completed his postdoctoral studies at the University of California, San Diego. He became a full Professor at the University of British Columbia in 1989, and retired in 2012 with the title of Professor Emeritus. He is the co-founder of Vancouver Biotech Ltd. He has published more than 200 papers, including 30 papers in cancer research. He has been serving as an editorial board member of the Journal of Carcinogenesis and Mutagenesis, and the Journal of Cancer Science and Therapy since 2012.

Carcinogenesis and Mutagenesis

Graduated MBBS University of Singapore (1965), FRACP (1975), FRCPA (1975), PhD (1977) and DSc (1986) Monash University. Heads the Autoimmunity Laboratory, Centre for Inflammatory Diseases, Department of Medicine, Monash University Faculty of Medicine and the Diagnostic Immunology Laboratory of Australian Clinical Laboratories, Clayton, Victoria. He has held positions as Head, Department of Immunology, Monash University (1995-2005) and was Chief Examiner in Immunology for the FRCPA (1995-2000). He has published 272 peer-reviewed papers, and 21 book chapters. He is currently engaged in studies directed towards understanding the immunopathology of atherosclerosis, based upon his extensive experience in the immunopathology of autoimmune gastritis and pernicious anaemia, autoimmune hepatitis and the molecular biology of early endosomes.

Immunology

Heather Medbury is a Senior Research Fellow at the University of Sydney, and is based at Westmead Hospital. She completed her PhD in transplant immunology before transferring to Vascular Biology to work for Professor John Fletcher, the head of Surgery for the University. Heather established laboratory based research for the Department of Surgery at Westmead Hospital which, combined with the large animal work operating in the Department, become known as the Vascular Biology Research Centre. Her work has received oral presentations at national and international meetings including at the American Heart Association (2004) and International Atherosclerosis Society meetings

Our research focus is cardiovascular disease. It is not just a global problem, but likely a personal one, as it doesn't just happen in someone else's family, but often within your own. Despite current treatments, patients with cardiovascular disease have a considerable residual risk of experiencing a clinical event (such as a heart attack or stroke). A challenge now is to develop strategies to prevent these remaining cardiovascular events. Though inflammation is thought to be a key contributor to residual risk, it is not a current treatment target. For the benefit of anti-inflammatory treatments to outweigh the risks, specific approaches will be required. A potential treatment target is the monocyte, as monocyte derived cells play a key role atherosclerotic plaque development and progression. Thus the focus of our group is to redefine the role of monocytes and macrophages in atherosclerosis in order to identify targets for therapeutic manipulation that could stabilize the disease. This will potentially result in a reduction in events such as heart attack and stroke that will not only decrease the morbidity and mortality associated with the disease but also limit the associated, health, social and economic burdens it poses.

Partnership Science and Research for One Health & Preventive medicine

Immunology

Dr Hasan Mahmud has made substantial contributions to the field of hematology and hematological malignancies last 12 years. Currently, he joined in a CAR-T cells research and development team in a world renounced biotech company in Maryland USA. His recent work at Stephenson Cancer Center, University of Oklahoma, USA focused on B-cell chronic lymphocytic leukemia (CLL) biology and tumor microenvironment. Previously, he served as a Senior Scientist at Pediatric Oncology and Hematology department at University of Groningen, The Netherlands where he identified therapeutic targets for Acute Myeloid Leukemia. Dr. Mahmud completed Ph.D. from the University of Tübingen, Germany where he investigated the mechanism and regulation of erythrocyte suicidal death and its contribution to Anemia. Dr. Mahmud has an extensive documented record of authorship in his field of endeavor. As evidence of this research success, Dr. Mahmud’s work has resulted in 42 peer-reviewed scientific articles and 1 letter to the editor in the most prestigious journals in the field. Dr. Mahmud is regularly conducting peer review for several journals and also serves as a member on the editorial board of the different journals in the field.

hematological malignancies, B-cell chronic lymphocytic leukemia (CLL) biology,Tumor microenvironment,Pediatric Oncology

A mathematician with over 10 years expertise in actively managing innovation in life science companies, Olga Kubassova, PhD, is a healthcare innovator and biotech investor with passion for improving people’s health. She has co-authored over 60 publications, books and book chapters, has become a scientific adviser to the UK government and EU funding bodies. She is a founder and CEO of IAG, Image Analysis Group, the imaging clinical research organization working with top bio-pharma companies to maximize their chances of brining novel therapeutic agents to the market. She is a four-time winner of national and international "Entrepreneur of the Year" awards. Olga’s ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice and research, while expanding IAG's footprint and partnerships.

Immunology

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Distinguished Professor and Academic Tenure of Chemistry and also Enrico Fermi Distinguished Chair in Molecular Spectroscopy at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA.

His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc.

Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress.

Dr. Ian James Martins from Australia conferred with Honorary Degree of Doctor of Science for Outstanding Scientific Contribution in Nutrition. Trophy of the World Championship Honorary Doctor of Science and Medicine.

Ahmed G Hegazi is currently a Professor of Microbiology and Immunology in the department of Zoonotic Diseases, National Research Center, Egypt. Prof. Hegazi received his masters degree in 1979, and his PhD in 1981. Hegazi's research work has been focused lately on bee products and their therapeutic effects. Hegazi Organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 166 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA). Awards First Class Decoration of Excellence, Egypt, 1995 The Senior Scientist Prize of National Research Center, Cairo, Egypt, 1996 The National Scientific Prize In Biological Sciences, Egypt, 1990 The Scientific Prize of The National Research Center, Cairo, Egypt, 1989 The Second Best Research Paper Award, International Congress of Propolis, Bones Airs, Argentina, 2000 Main Speaker Award,10th Academic Conference, PRA and NAS (Nippon Apitherapy Soc.) Japan, 2006 2 Bronze medals from The International Innovation Fair of the Middle East, Kuwait, 2007 Patents Patent No. 8901 at 22/08/2006: A novel drug from natural products with new therapeutic modalities in treatment of psoriasis Patent No. 1005 at 02/01/2006: A novel drug from natural resources for controlling Fascioliasis Patent No. 270: at 01/06/2005: A novel drug from medicinal plants with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties. Patent No. 272: at 01/06/2005: A novel drug from natural resources with antiatherosclerotic (hypocholesterolaemic), antioxidant and cardio protective properties. Scientific Activities Editor in the following International Journals: Research Journal of Allergy, 2007 International Journal of Virology, 2007 Current Research In Tuberculosis, 2007 Research Journal of Veterinary Science, 2007 Research Journal of Microbiology, 2007 International Journal of Cancer Research, 2007 Research Journal of Medicinal plants, 2007 Referee in the following International Journals: Journal of Planta Medica, 2005 Journal of Evidence Based Complementary and Alternative Medicine, 2006 International Journal of Radiation Biology, 2007 Close

Microbiology and Immunology

Prof. Dr. Ignat Ignatov DSc was born on January 1, 1963 in Bulgaria. In 1989 Ignatov majored in physics from “Kliment Ohridski” Sofia University with master degree. In 1996 he founded the Scientific Research Center of Medical Biophysics. Prof. Ignatov was a consultant of the National Center of Public Health at the Ministry of Health until 2003. The Bulgarian scientist is involved in research projects for the study of biophysical and medical effects in the application of methodics for the influencing of human health. From 2007 Ignatov is honorable doctor in European Academy of Natural Sciences (Germany). From 2013 he is Doctor of Science and Professor in The Russian Academy for Natural History. From 1998 Prof. Ignatov is co-autor with Prof. Anton Antonov of spectral method Differential Non-equilibrium energy spectrum (DNES). In 2007, Bulgarian scientist created the Method of the color coronal spectral analysis. The method examines the biophysical status of a person. In 2010 Prof. Ignatov, together with Ass. Prof. Mosin (1966-2016) from Russia, created a concept for the origination of life and living matter in hot mineral water. As of 2012, research has been undertaken in Bulgaria on the scientific and practical project “Factors of Longevity”. In the field of electrochemically activated water (anolyte and catholyte) Prof. Ignatov carried out scientific research in group from the Bulgarian Academy of Sciences (BAS).with head Assoc. Prof. Georgi Gluhchev Prof. Ignatov has more than 400 scientific publications. From 2001 Prof. Ignatov has research projects with Prof. Christos Drossinakis from Frankfurt, Germany for bio effects in model systems. Prof. Ignatov is chief editor of two US scientific journals and in editorial board of eight EU and US journals.

Structure of water, origination of life and living matter, mountain water and longevity, high frequency color coronal discharge, nanotechnologies, astrobiology, biological effects in heavy water, entropy and time in living matter, visual analyzer, biophysical fields, biotechnologies, shungite.

Mr. De la Parra is an entrepreneur focused on Information Technology, Education and Health. He is creative and results-driven and has 16+ years of Digital Strategy experience in architecture and implementation. Mr. De la Parra is the COO and Co-founding Partner at The Solomon Brokerage Firm. He currently leads as CEO at Mass Media Division & De la Parra Mobile Solutions, while also being the President of PetroM Renewable, VP of Operations & Strategy at PetroM Logistics, both divisions of PetroM Corp. Former COO & Co-founder at RegenerAge® Clinic & RegenerAge® Beauty & a member of the Board of Advisors. Former CEO & Founder at Astrum Salud Móvil and its Telemedicine service Astrum Móvil, former Digital Strategy Director & Co-founder at Dr. Jois®, BiorganicAging®, What Skin Needs™/WSN International Pty. Ltd. He also served as a member of the Board of Advisors and is former CMO at ReAnima Advanced Biosciences and former Digital Media Director at Bioquark, Inc. Within the academic and educational fields, Mr. De la Parra acted as the Executive Vice President: Executive Chairman of the WAMS Mobile Health Division, WAMS Chief Coordinating Officer, a member of the WAMS Executive Council (WAMS Executive Board), a member of the WAMS Education & Training Board (ETB), a member of the WAMS Editorial Board, an Honorary Member of the Academy Faculty FWAMS, an Honorary Fellow of the Academy & is also a Senior Partner at WAMS, The World Academy of Medical Sciences. He is also an Advisory Board member, functioned as the Chief Operating Officer and is a Co-founding Partner at The Reprogramming Medicine Association. Mr. De la Parra is also a member of the National Introducing Brokers Association and a part of the National Biofuel Board, (Alliance Program), also being the founder and former Board of Directors member of Astrum Fundación, an Advisory Board member of the Lifeboat Foundation, an Advisory Board member of the Future Worlds Center - Cyprus Neuroscience & Technology Institute (Senior TV Program), a Federated member of the International Longevity Alliance, and volunteered as Digital Strategy adviser at the Major Mouse Testing Program. He is also a member of the Web Committee at the Life Extension Advocacy Foundation / Lifespan.io and has volunteered with SENS Research Foundation for the OncoSENS Program in Digital Strategy. Alejandro De la Parra Solomon is on Google+, Facebook, and on LinkedIn.

Talks about mobile health, public policy, education technology, and information technology